pentoxifylline has been researched along with Kidney Failure, Chronic in 36 studies
Kidney Failure, Chronic: The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We aimed to investigate the effect of pentoxifylline on adequacy of dialysis, anemia, inflammatory cytokines, and biochemical markers in patients with ESRD on hemodialysis." | 9.34 | Effect of Pentoxifylline on Inflammatory Cytokines, Adequacy of Dialysis, Anemia and Biochemical Markers of Hemodialysis Patients: a Randomized Controlled Trial. ( Doustimotlagh, AH; Larki, RA; Manzouri, L; Sedaghattalab, M; Talebi, V, 2020) |
| "Pentoxifylline may decrease proteinuria in non-diabetic patients with CKD." | 9.14 | Effect of pentoxifylline on proteinuria, markers of tubular injury and oxidative stress in non-diabetic patients with chronic kidney disease - placebo controlled, randomized, cross-over study. ( Aleksandrowicz, E; Knap, N; Neuwelt, A; Renke, M; Rutkowski, B; Rutkowski, P; Tylicki, L; Woźniak, M; Zietkiewicz, M; Łysiak-Szydłowska, W, 2010) |
| "Pentoxifylline has been shown to have modulatory effects on the immune system." | 6.79 | Evaluation of the effect of pentoxifylline on erythropoietin-resistant anemia in hemodialysis patients. ( Charkazi, S; Khaiat, MH; Mohammadpour, AH; Naghibi, M; Nazemian, F; Salari, P; Shamsara, J; Tafaghodi, M, 2014) |
| " Conclusion of this review is that short-term use of PTF may produce a significant reduction of proteinuria in subjects with diabetic and also non-diabetic kidney diseases but the reports of long-term use of PTF also show that urinary protein excretion exhibits a progressive and sustained reduction in patients treated with PTF." | 6.47 | A review of the potential benefits of pentoxifylline in diabetic and non-diabetic proteinuria. ( Abdollahi, M; Badri, S; Dashti-Khavidaki, S; Lessan-Pezeshki, M, 2011) |
| " We aimed to investigate the effect of pentoxifylline on adequacy of dialysis, anemia, inflammatory cytokines, and biochemical markers in patients with ESRD on hemodialysis." | 5.34 | Effect of Pentoxifylline on Inflammatory Cytokines, Adequacy of Dialysis, Anemia and Biochemical Markers of Hemodialysis Patients: a Randomized Controlled Trial. ( Doustimotlagh, AH; Larki, RA; Manzouri, L; Sedaghattalab, M; Talebi, V, 2020) |
| "Inflammation is a risk factor for mortality in patients with chronic renal failure (CRF)." | 5.34 | Inflammation and oxidative stress markers by pentoxifylline treatment in rats with chronic renal failure and high sodium intake. ( Amato, D; de Carmen Prado-Uribe, M; Gallardo, JM; Paniagua, R, 2007) |
| "In contrast to previous studies, our data do not support the concept that pentoxifylline elevates hemoglobin level and improves anemia, Further studies on a larger number of patients are required to assess whether or not pentoxifylline is useful in these patients." | 5.16 | Role of pentoxifylline in treatment of anemic patients suffering chronic hemodialysis: a randomized clinical trial. ( Atapour, A; Dolatkhah, S; Mortazavi, M; Naini, AE; Nasiri, R; Seyrafian, S; Taheri, S, 2012) |
| "Pentoxifylline may decrease proteinuria in non-diabetic patients with CKD." | 5.14 | Effect of pentoxifylline on proteinuria, markers of tubular injury and oxidative stress in non-diabetic patients with chronic kidney disease - placebo controlled, randomized, cross-over study. ( Aleksandrowicz, E; Knap, N; Neuwelt, A; Renke, M; Rutkowski, B; Rutkowski, P; Tylicki, L; Woźniak, M; Zietkiewicz, M; Łysiak-Szydłowska, W, 2010) |
| "To determine if there is sufficient evidence to recommend the addition of pentoxifylline to standard ACE inhibitor and ARB therapy in chronic kidney disease patients to reduce proteinuria and preserve kidney function." | 4.93 | Can Pentoxifylline be used as Adjunct Therapy to ACE Inhibitors and ARBs in Preserving Kidney Function? ( Al-Makki, A; Carson, C; Shepler, B, 2016) |
| "We investigated the ability of pentoxifylline, a drug with hemorheological actions known to block tumor necrosis factor-alpha (TNF-alpha) release, to modulate whole-body protein kinetics in undialyzed patients with chronic uremia." | 3.71 | Pentoxifylline acutely reduces protein catabolism in chronically uremic patients. ( Biolo, G; Bosutti, A; Ciocchi, B; Guarnieri, G; Situlin, R; Toigo, G, 2002) |
| "Pentoxifylline has been shown to have modulatory effects on the immune system." | 2.79 | Evaluation of the effect of pentoxifylline on erythropoietin-resistant anemia in hemodialysis patients. ( Charkazi, S; Khaiat, MH; Mohammadpour, AH; Naghibi, M; Nazemian, F; Salari, P; Shamsara, J; Tafaghodi, M, 2014) |
| "For pentoxifylline-treated participants, the mean estimated GFR decrease during treatment was slower compared with the year before study enrollment (-9." | 2.74 | Effect of pentoxifylline on GFR decline in CKD: a pilot, double-blind, randomized, placebo-controlled trial. ( Aboudara, MC; Cushner, HM; Olson, SW; Perkins, RM; Uy, AL; Yuan, CM, 2009) |
| " Secondary outcome measures will include erythropoiesis stimulating agent dosage, Key's index (erythropoiesis stimulating agent dosage divided by haemoglobin concentration), and blood transfusion requirement." | 2.73 | Oxpentifylline versus placebo in the treatment of erythropoietin-resistant anaemia: a randomized controlled trial. ( Beller, E; Cass, A; Fassett, RG; Ferrari, P; Hawley, CM; Johnson, DW; MacDonald, S; Pedagogos, E; Rosser, B; Thompson, C, 2008) |
| "Diabetic nephropathy, or diabetic kidney disease (DKD), is the most serious complication of diabetes mellitus (DM)." | 2.53 | Pentoxifylline for Diabetic Nephropathy: an Important Opportunity to Re-purpose an Old Drug? ( Bhanot, S; Leehey, DJ, 2016) |
| " Conclusion of this review is that short-term use of PTF may produce a significant reduction of proteinuria in subjects with diabetic and also non-diabetic kidney diseases but the reports of long-term use of PTF also show that urinary protein excretion exhibits a progressive and sustained reduction in patients treated with PTF." | 2.47 | A review of the potential benefits of pentoxifylline in diabetic and non-diabetic proteinuria. ( Abdollahi, M; Badri, S; Dashti-Khavidaki, S; Lessan-Pezeshki, M, 2011) |
| "However, the ultimate solution to halt disease progression in the long term is still pending." | 2.42 | Pentoxifylline: a potential therapy for chronic kidney disease. ( Chen, WY; Chen, YM; Chiang, WC; Lin, SL; Tsai, TJ, 2004) |
| "In terms of the risks of developing ESRD, pentoxifylline alone exerted a comparable beneficial effect to combined therapy with an RAAS inhibitor and greater renoprotection than RAAS inhibitor monotherapy." | 1.42 | Pentoxifylline Decreases Dialysis Risk in Patients With Advanced Chronic Kidney Disease. ( Chen, CY; Chen, L; Chen, YM; Huang, TM; Lin, CJ; Lin, SL; Pan, CF; Wu, CH; Wu, CJ; Wu, PC; Wu, VC, 2015) |
| "Inflammation is a risk factor for mortality in patients with chronic renal failure (CRF)." | 1.34 | Inflammation and oxidative stress markers by pentoxifylline treatment in rats with chronic renal failure and high sodium intake. ( Amato, D; de Carmen Prado-Uribe, M; Gallardo, JM; Paniagua, R, 2007) |
| "Pentoxifylline (PTX) is a phosphodiesterase inhibitor that possesses antiproteinuric effect and has been proved to be effective in treating several glomerular diseases." | 1.34 | Effect of pentoxifylline on graft function of renal transplant recipients complicated with chronic allograft nephropathy. ( Chen, CH; Cheng, CH; Lian, JD; Lu, YS; Shu, KH; Wu, MJ, 2007) |
| "Sensorineural hearing loss is frequently found in the patients under the treatment with hemodialysis, but the responsible etiological factor(s) still remains controversial." | 1.28 | The hearing of the patients treated with hemodialysis: a long term follow-up study. ( Hara, A; Igari, T; Kusakari, J; Suzuki, S; Takeyama, M, 1992) |
| " Consequently, when a dialysis patient required this drug, we started at a low dose and gradually increased the dosage while monitoring the patient for signs or symptoms of toxicity and following plasma concentrations of parent drug and its metabolites." | 1.27 | Pentoxifylline in end-stage renal disease. ( Kroboth, PD; Silver, MR, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (8.33) | 18.7374 |
| 1990's | 6 (16.67) | 18.2507 |
| 2000's | 10 (27.78) | 29.6817 |
| 2010's | 16 (44.44) | 24.3611 |
| 2020's | 1 (2.78) | 2.80 |
| Authors | Studies |
|---|---|
| Yang, H | 1 |
| Juang, SY | 1 |
| Liao, KF | 1 |
| Chen, YH | 1 |
| Sedaghattalab, M | 1 |
| Talebi, V | 1 |
| Manzouri, L | 1 |
| Larki, RA | 1 |
| Doustimotlagh, AH | 1 |
| Chen, YM | 5 |
| Chiang, WC | 4 |
| Lin, SL | 4 |
| Tsai, TJ | 3 |
| Lin, YC | 1 |
| Chang, YH | 1 |
| Yang, SY | 1 |
| Wu, KD | 1 |
| Chu, TS | 1 |
| Mohammadpour, AH | 1 |
| Nazemian, F | 1 |
| Khaiat, MH | 1 |
| Tafaghodi, M | 1 |
| Salari, P | 1 |
| Charkazi, S | 1 |
| Naghibi, M | 1 |
| Shamsara, J | 1 |
| Wu, PC | 1 |
| Wu, CJ | 1 |
| Lin, CJ | 1 |
| Pan, CF | 1 |
| Chen, CY | 1 |
| Huang, TM | 1 |
| Wu, CH | 1 |
| Chen, L | 1 |
| Wu, VC | 1 |
| Bhanot, S | 1 |
| Leehey, DJ | 1 |
| Lai, TS | 1 |
| Carson, C | 1 |
| Al-Makki, A | 1 |
| Shepler, B | 1 |
| Pena-Polanco, JE | 1 |
| Fried, LF | 1 |
| Soltani, P | 1 |
| Ketabi Moghaddam, P | 1 |
| Haghverdi, F | 1 |
| Cheraghi, A | 1 |
| Johnson, DW | 1 |
| Hawley, CM | 1 |
| Rosser, B | 1 |
| Beller, E | 1 |
| Thompson, C | 1 |
| Fassett, RG | 1 |
| Ferrari, P | 1 |
| MacDonald, S | 1 |
| Pedagogos, E | 1 |
| Cass, A | 1 |
| Perkins, RM | 1 |
| Aboudara, MC | 1 |
| Uy, AL | 1 |
| Olson, SW | 1 |
| Cushner, HM | 1 |
| Yuan, CM | 1 |
| Hamidian Jahromi, A | 1 |
| Kessaris, N | 1 |
| Sharifian, M | 1 |
| Roozbeh, J | 1 |
| Renke, M | 1 |
| Tylicki, L | 1 |
| Rutkowski, P | 1 |
| Knap, N | 1 |
| Zietkiewicz, M | 1 |
| Neuwelt, A | 1 |
| Aleksandrowicz, E | 1 |
| Łysiak-Szydłowska, W | 1 |
| Woźniak, M | 1 |
| Rutkowski, B | 1 |
| Shah, SV | 1 |
| Badri, S | 1 |
| Dashti-Khavidaki, S | 1 |
| Lessan-Pezeshki, M | 1 |
| Abdollahi, M | 1 |
| González-Espinoza, L | 1 |
| Rojas-Campos, E | 1 |
| Medina-Pérez, M | 1 |
| Peña-Quintero, P | 1 |
| Gómez-Navarro, B | 1 |
| Cueto-Manzano, AM | 1 |
| Mortazavi, M | 1 |
| Seyrafian, S | 1 |
| Taheri, S | 1 |
| Nasiri, R | 1 |
| Dolatkhah, S | 1 |
| Naini, AE | 1 |
| Atapour, A | 1 |
| Ji, Q | 1 |
| Liu, J | 1 |
| Gong, D | 1 |
| Biolo, G | 1 |
| Ciocchi, B | 1 |
| Bosutti, A | 1 |
| Situlin, R | 1 |
| Toigo, G | 1 |
| Guarnieri, G | 1 |
| Macdougall, IC | 1 |
| Chen, WY | 1 |
| Lai, CF | 1 |
| Hsieh, BS | 1 |
| Gallardo, JM | 1 |
| de Carmen Prado-Uribe, M | 1 |
| Amato, D | 1 |
| Paniagua, R | 1 |
| Shu, KH | 1 |
| Wu, MJ | 1 |
| Chen, CH | 1 |
| Cheng, CH | 1 |
| Lian, JD | 1 |
| Lu, YS | 1 |
| Pilotovich, VS | 1 |
| Kozlov, GT | 1 |
| Tukaĭ, NI | 1 |
| Kharchenko, AS | 1 |
| Ivanova, NS | 1 |
| Ferrà, C | 1 |
| de Sanjosé, S | 1 |
| Lastra, CF | 1 |
| Martí, F | 1 |
| Mariño, EL | 1 |
| Sureda, A | 1 |
| Brunet, S | 1 |
| Gallardo, D | 1 |
| Berlanga, JJ | 1 |
| García, J | 2 |
| Grañena, A | 1 |
| Navarro, JF | 2 |
| Mora, C | 2 |
| Rivero, A | 1 |
| Macía, M | 2 |
| Gallego, E | 1 |
| Méndez, ML | 1 |
| Chahin, J | 1 |
| Briggs, WA | 1 |
| Eustace, J | 1 |
| Gimenez, LF | 1 |
| Choi, MJ | 1 |
| Scheel, PJ | 1 |
| Burdick, JF | 1 |
| Schaefer, K | 1 |
| von Herrath, D | 1 |
| Hensel, A | 1 |
| Grigoleit, HG | 1 |
| Kusakari, J | 1 |
| Hara, A | 1 |
| Takeyama, M | 1 |
| Suzuki, S | 1 |
| Igari, T | 1 |
| Rayner, BL | 1 |
| Pascoe, MD | 1 |
| Thebus, G | 1 |
| Sharma, AK | 1 |
| Gupta, R | 1 |
| Chablani, P | 1 |
| Sharma, P | 1 |
| Silver, MR | 1 |
| Kroboth, PD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effects of Calcitriol on Podocytes in Diabetic Kidney Disease Patients: Assessment of Urine Podocin, Urine Nephrin, Urine Interleukin-6, Urine KIM-1, Plasma Renin, and Albuminuria[NCT05298163] | 120 participants (Anticipated) | Interventional | 2022-04-30 | Not yet recruiting | |||
| Pentoxifylline and Progression of Chronic Kidney Disease in Moderate-to-high Risk Patients: a Pilot Randomized, Placebo-controlled, Double-blind Trial.[NCT00285298] | Phase 3 | 39 participants (Actual) | Interventional | 2006-01-31 | Completed | ||
| Effect of Pentoxifylline Administration on Hemoglobin Level of Hemodialysis Patients[NCT03731741] | Phase 2 | 57 participants (Actual) | Interventional | 2017-11-01 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
10 reviews available for pentoxifylline and Kidney Failure, Chronic
| Article | Year |
|---|---|
Therapeutic efficacy of pentoxifylline on proteinuria and renal progression: an update.
Topics: Disease Progression; Kidney Failure, Chronic; Pentoxifylline; Phosphodiesterase Inhibitors; Proteinu | 2017 |
Update of pathophysiology and management of diabetic kidney disease.
Topics: Albuminuria; Biomarkers; Diabetic Nephropathies; Disease Progression; Humans; Kidney Failure, Chroni | 2018 |
Pentoxifylline for Diabetic Nephropathy: an Important Opportunity to Re-purpose an Old Drug?
Topics: Animals; Clinical Trials as Topic; Diabetic Nephropathies; Disease Progression; Humans; Kidney Failu | 2016 |
Can Pentoxifylline be used as Adjunct Therapy to ACE Inhibitors and ARBs in Preserving Kidney Function?
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Diabetes Mellit | 2016 |
Established and Emerging Strategies in the Treatment of Chronic Kidney Disease.
Topics: Allopurinol; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Bicarbonate | 2016 |
Progress toward novel treatments for chronic kidney disease.
Topics: Amides; Anticoagulants; Antihypertensive Agents; Bicarbonates; Chronic Disease; Enzyme Inhibitors; F | 2010 |
A review of the potential benefits of pentoxifylline in diabetic and non-diabetic proteinuria.
Topics: Animals; Chronic Disease; Diabetic Nephropathies; Disease Progression; Humans; Kidney Diseases; Kidn | 2011 |
Could anti-inflammatory cytokine therapy improve poor treatment outcomes in dialysis patients?
Topics: CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cytokines; Epoetin Alfa; Erythropoietin; Hum | 2004 |
Pentoxifylline: a potential therapy for chronic kidney disease.
Topics: Animals; Anti-Inflammatory Agents; Cell Division; Disease Progression; Extracellular Matrix; Glomeru | 2004 |
The renoprotective potential of pentoxifylline in chronic kidney disease.
Topics: Cell Proliferation; Diabetic Nephropathies; Humans; Kidney Failure, Chronic; Pentoxifylline; Phospho | 2005 |
10 trials available for pentoxifylline and Kidney Failure, Chronic
| Article | Year |
|---|---|
Effect of Pentoxifylline on Inflammatory Cytokines, Adequacy of Dialysis, Anemia and Biochemical Markers of Hemodialysis Patients: a Randomized Controlled Trial.
Topics: Anemia; Biomarkers; C-Reactive Protein; Cytokines; Humans; Kidney Failure, Chronic; Pentoxifylline; | 2020 |
Evaluation of the effect of pentoxifylline on erythropoietin-resistant anemia in hemodialysis patients.
Topics: Adult; Anemia; Biomarkers; Drug Resistance; Drug Substitution; Erythropoiesis; Erythropoietin; Femal | 2014 |
A Randomized Clinical Trial of the Effect of Pentoxifylline on C-Reactive Protein Level and Dialysis Adequacy in End-stage Renal Disease Patients on Maintenance Hemodialysis.
Topics: Aged; Blood Urea Nitrogen; C-Reactive Protein; Double-Blind Method; Female; Free Radical Scavengers; | 2016 |
Oxpentifylline versus placebo in the treatment of erythropoietin-resistant anaemia: a randomized controlled trial.
Topics: Adult; Anemia; Blood Cell Count; Blood Transfusion; Darbepoetin alfa; Double-Blind Method; Drug Resi | 2008 |
Effect of pentoxifylline on GFR decline in CKD: a pilot, double-blind, randomized, placebo-controlled trial.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Chronic Dis | 2009 |
Effect of pentoxifylline on proteinuria, markers of tubular injury and oxidative stress in non-diabetic patients with chronic kidney disease - placebo controlled, randomized, cross-over study.
Topics: Adolescent; Adult; Aged; Blood Pressure; Cross-Over Studies; Female; Humans; Kidney Failure, Chronic | 2010 |
Pentoxifylline decreases serum levels of tumor necrosis factor alpha, interleukin 6 and C-reactive protein in hemodialysis patients: results of a randomized double-blind, controlled clinical trial.
Topics: Adult; Anti-Inflammatory Agents; Biomarkers; C-Reactive Protein; Double-Blind Method; Female; Humans | 2012 |
Role of pentoxifylline in treatment of anemic patients suffering chronic hemodialysis: a randomized clinical trial.
Topics: Anemia; Female; Hemoglobins; Humans; Iron; Kidney Failure, Chronic; Male; Middle Aged; Pentoxifyllin | 2012 |
Pentoxifylline, ciprofloxacin and prednisone failed to prevent transplant-related toxicities in bone marrow transplant recipients and were associated with an increased incidence of infectious complications.
Topics: Adolescent; Adult; Anti-Infective Agents; Anti-Inflammatory Agents; Bacterial Infections; Bone Marro | 1997 |
Renal failure, anaemia, cytokines and inflammation.
Topics: Anemia; Creatinine; Cytokines; Hematocrit; Hemoglobins; Humans; Inflammation; Kidney Failure, Chroni | 2001 |
16 other studies available for pentoxifylline and Kidney Failure, Chronic
| Article | Year |
|---|---|
Comparing the Effect of Folic Acid and Pentoxifylline on Delaying Dialysis Initiation in Patients with Advanced Chronic Kidney Disease.
Topics: Adult; Aged; Aged, 80 and over; Combined Modality Therapy; Disease Progression; Female; Folic Acid; | 2019 |
Pentoxifylline Decreases Dialysis Risk in Patients With Advanced Chronic Kidney Disease.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; | 2015 |
Pentoxifylline: Evidence strong enough for renoprotection?
Topics: Diabetic Nephropathies; Humans; Kidney Failure, Chronic; Pentoxifylline; Phosphodiesterase Inhibitor | 2016 |
Protective effect of pentoxifylline in the kidney perfusion fluid on the transplanted kidney.
Topics: Animals; Humans; Kidney Failure, Chronic; Kidney Transplantation; Organ Preservation; Pentoxifylline | 2009 |
Could Pentoxifylline (PTX) be a promising agent to reduce the systemic inflammation in hemodialysis patients?
Topics: C-Reactive Protein; Female; Humans; Interleukin-6; Kidney Failure, Chronic; Male; Pentoxifylline; Re | 2012 |
Pentoxifylline acutely reduces protein catabolism in chronically uremic patients.
Topics: Amino Acids; Carbon Dioxide; Carbon Isotopes; Chronic Disease; Drug Administration Schedule; Female; | 2002 |
Inflammation and oxidative stress markers by pentoxifylline treatment in rats with chronic renal failure and high sodium intake.
Topics: Animals; Biomarkers; Creatinine; Free Radical Scavengers; Inflammation; Kidney Failure, Chronic; Mal | 2007 |
Effect of pentoxifylline on graft function of renal transplant recipients complicated with chronic allograft nephropathy.
Topics: Acetylglucosaminidase; Adult; Aged; Biomarkers; Biopsy; Creatinine; Cytokines; Female; Follow-Up Stu | 2007 |
[Potentials of conservative therapy in chronic kidney failure].
Topics: Adult; Charcoal; Diarrhea; Disseminated Intravascular Coagulation; Drug Evaluation; Humans; Kidney F | 1982 |
Effects of pentoxifylline on the haematologic status in anaemic patients with advanced renal failure.
Topics: Aged; Anemia; Diabetic Nephropathies; Erythropoietin; Female; Hematologic Agents; Humans; Kidney Fai | 1999 |
Lymphocyte suppression by glucocorticoids with cyclosporine, tacrolimus, pentoxifylline, and mycophenolic acid.
Topics: Cells, Cultured; Cyclosporine; Drug Combinations; Enzyme Inhibitors; Glucocorticoids; Humans; Immuno | 1999 |
[Investigations on the pharmacokinetics of pentoxifylline in chronic renal failure (authors transl)].
Topics: Administration, Oral; Aged; Creatinine; Humans; Kidney Failure, Chronic; Male; Middle Aged; Pentoxif | 1977 |
The hearing of the patients treated with hemodialysis: a long term follow-up study.
Topics: Adult; Audiometry, Pure-Tone; Female; Follow-Up Studies; Hearing Loss, Bilateral; Hearing Loss, Sens | 1992 |
Pentoxifylline does not prevent haemodialysis induced neutropaenia or hypoxaemia.
Topics: Humans; Hypoxia; Kidney Failure, Chronic; Leukocyte Count; Neutropenia; Oxygen; Partial Pressure; Pe | 1992 |
Progression of renal failure: role of red cell deformability.
Topics: Adult; Erythrocyte Deformability; Female; Humans; Kidney Failure, Chronic; Male; Middle Aged; Pentox | 1991 |
Pentoxifylline in end-stage renal disease.
Topics: Adult; Dose-Response Relationship, Drug; Female; Hand; Humans; Ischemia; Kidney Failure, Chronic; Pe | 1987 |